Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ensartinib - Betta Pharmaceuticals/Xcovery

Drug Profile

Ensartinib - Betta Pharmaceuticals/Xcovery

Alternative Names: X-396

Latest Information Update: 06 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xcovery
  • Developer Cancer Research Institute; Ludwig Institute for Cancer Research; MedImmune; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Xcovery Holdings
  • Class Antineoplastics; Piperazines; Pyridazines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; EphA2 receptor antagonists; Proto oncogene protein c met inhibitors; ROS1 protein inhibitors; TrkA receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II CNS cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 31 Oct 2019 Xcovery initiates an expanded access programme for Non-small cell lung cancer (Second-line therapy or greater) in USA (PO) (NCT04146571)
  • 28 Dec 2018 Betta Pharmaceuticals initiates enrolment in a phase I trial for Non-small cell lung cancer (In volunteers) in China (PO) (NCT03804541)
  • 20 Dec 2018 Additional efficacy data from a phase I/II trial in Non-small cell lung cancer and Solid tumours presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top